STORM THERAPEUTICS - Key Persons

Job Titles:

• Director of Business Development
• Member of the Leadership Team
• Senior Director of Business Development and Alliance Management

Angus joined STORM Therapeutics as Director of Business Development in April 2020. Angus has over 15 years of business development experience working with biotech and pharmaceutical companies, and academia. Prior to STORM (from 2020), Angus was Associate Director Business Management & Transactions at Cancer Research UK Commercial Partnerships (previously Cancer Research Technology) where he led the deal team in major drug discovery alliances including CRT's biggest and highest value drug discovery alliance deal to date, with Celgene. Angus has a wealth of experience negotiating large numbers of licenses and collaborations as well as in the formation of company spin-outs including Mission Therapeutics and Azeria Therapeutics. Angus earned his BSc (Hons) in Molecular Biology from the University of Edinburgh and his PhD in Molecular and Cellular Biology from Institute of Cancer Research, University of London, before undertaking post-doctoral research studies at the MRC Laboratory of Molecular Biology in Cambridge.

Job Titles:

• Member of the Leadership Team
• Vice President Medicinal Chemistry

Beth Thomas has over 20 years of experience in medicinal and computational chemistry and joined STORM Therapeutics in 2016. Beth is responsible for medicinal chemistry strategy to enable the discovery and progression of clinical candidates from Storm's project portfolio. Beth has experience in industrial, academic and not-for-profit roles, leading inter-disciplinary drug discovery teams at Celltech, UCB, BioFocus, University of Cambridge and the Cambridge Crystallographic Data Centre. Beth has a BSc in Chemistry from the University of St Andrews and a PhD in polyketide biosynthesis with Professors Staunton and Leadlay at the University of Cambridge.

Job Titles:

• Member of the Board
• Vice President

Christopher is Vice President, WRDM and Partner at Pfizer Ventures. Chris is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. He currently has responsibility for Pfizer's investments in Adapsyn Bioscience, Arkuda Therapeutics, Arrakis Therapeutics, Kestrel Therapeutics, MindImmune, Mitokinin, Parthenon Therapeutics, Pyxis Oncology (PYXS), Storm Therapeutics, Strata Oncology and Triana Biomedicines. He is also responsible for managing our investment in the Mission BioCapital and Phoenix Venture Partners funds. His prior investment responsibilities include BioAtla (BCAB), Kymera Therapeutics (KYMR), Morphic Therapeutic (MORF) and Petra Pharma. Chris brings 20+ years of scientific leadership, a strong track record of delivering clinical candidates across multiple disease areas and modalities, and proven ability to build and lead highly engaged teams. He built and led the Applied Synthesis Technologies group within R&D to help accelerate the delivery of Pfizer's small molecule portfolio. Prior to that, Chris built and led Pfizer's Antibody Drug Conjugate Oncology Medicinal Chemistry group which delivered new linker, payload and conjugation methods resulting in over 7 conjugates entering clinical development. Chris started his career in the Neuroscience Medicinal Chemistry group where he invented and helped deliver numerous clinical candidates. Chris received his BS in Chemistry from the University of Illinois-Urbana/Champaign and his PhD in Chemistry from the University of Wisconsin-Madison and joined Pfizer after completing post-doctoral studies at the University of California - Irvine

Job Titles:

• Member of the Board
• Managing Director of M Ventures

Hakan is Managing Director of M Ventures and heads the Biotechnology investments covering Healthcare and Life Sciences. Hakan joined M Ventures in 2013 and has been investing in the sector for 15 years. Previously, Hakan was a partner at Aescap Venture investing in European opportunities. Hakan started his investment career at Atlas Venture where he was part of the investment team in London focusing on global investment opportunities in healthcare and medical technologies across US, Europe and Asia. He was instrumental in the creation and financing, business and R&D strategies of multiple companies in their formation years including Orphazyme, Bicycle, Nimbus Discovery, and f-Star while at Aescap and Atlas. Hakan continues his active investing role and represents M Ventures on multiple portfolio companies. He comes from an academic background receiving his Ph.D. in oncology from the Institute of Cancer Research/ University of London, UK and continuing his scientific career with post doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his B.Sc. Hons, from University College London. Hakan is based in Amsterdam at the M Ventures head office.

Job Titles:

• Chief Executive Officer
• Member of the Board
• Member of the Leadership Team
• President

Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience. With broad disease-area expertise and a specialty in oncology therapeutics, Jerry has held scientific, pharmaceutical and venture capital positions and has been the CEO or President of multiple biotechnology companies leading novel therapeutic programs from discovery, development to drug approvals for internal and in-licensed products. From 2016 to late 2021 Jerry was President and CEO of NASDAQ listed Harpoon Therapeutics building the Company from early stage through to IPO, follow-on financings, and development collaborations. Prior to that he held multiple positions, including President and CEO of Kolltan Pharmaceuticals which was acquired by Celldex, Innovative Medicine Head of Oncology and SVP at AstraZeneca-Medimmune, managing a more than $1 billion global R&D budget and President at SUGEN/Pfizer where he was instrumental in invention and full development of several ground-breaking protein kinase inhibitors including sunitinib (Sutent®). Jerry has also held academic appointments at the Yale Comprehensive Cancer Center at Yale University, Tufts University School of Medicine, and the Massachusetts Institute of Technology. He received his BS in biology and PhD in the field of biochemistry and genetics from Rensselaer Polytechnic Institute, has authored over 100 scientific and medical publications and is an inventor on over 60 US patents.

Job Titles:

• Member of the Board

John is a Non-executive Director in European biotech companies: Adcendo, Agomab, CatalYm, Neophore, Storm, Synklino. He was the CEO of F-star in Cambridge, UK (2012-2018), where he built a successful biotech company that initiated two clinical trials in oncology and generated more than 200M in non-dilutive revenue. Previously he was VP Research at ImClone Systems, New York (2010-2012) and cofounder and Chief Scientific Officer of Symphogen A/S, Denmark (2000-2009). After graduating in Medicine in Aarhus Denmark 1992, Dr. Haurum received a D.Phil. in Immunology from the Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, England. Subsequently, he took up positions as Associate Professor at the Danish Cancer Society and completed his medical training.

Job Titles:

• Chief Medical Officer
• Member of the Leadership Team
• Medical Advisor to the European Commission

Josefin-Beate joined STORM Therapeutics as Chief Medical Officer in June 2020. Josefin-Beate has over 25 years' experience in pharmaceutical drug development in Europe and North America. She has held executive managerial positions at international pharmaceutical & biotech companies Ablynx, GPC-Biotech, Gilead Sciences, Bristol-Myers Squibb and LEO Pharma. Josefin-Beate has worked on more than 50 disease targets at various stages of clinical validation across oncology, immunology and other indications. Josefin-Beate is a medical advisor to the European Commission and is member of various medical associations such as ASCO, ESMO and SITC. She provides clinical advice and part-time CMO support for SMEs and biotech companies. Dr. Holz received her PhD in Haematology Oncology from the University Marburg, Germany in 1995.

Job Titles:

• Chartered Management Accountant
• Chief Financial Officer
• Member of the Leadership Team

Margaret is the Chief Financial Officer of STORM Therapeutics and is an experienced CFO providing CFO services to prominent biotech Companies and is the Co-founder of Daniel-Bradshaw Ltd, a bespoke CFO and Accounting Services Company to the biotech sector. Margaret is a Chartered Management Accountant who also holds a certificate in Company Direction from the Institute of Directors and has over 10 years' experience as a Finance Director and various CFO roles. In addition to supporting STORM Therapeutics and Bradshaw Daniel Ltd, Margaret has worked in both international and UK Groups and is currently providing CFO services to a number of Biotech Life Sciences companies which include GammaDelta Therapeutics Ltd, Apollo Therapeutics LLP, and Adaptate Biotherapeutics Ltd.

Job Titles:

• Member of the Leadership Team
• Senior Vice President Therapeutics

Matthew Fyfe has over 20 years' experience in drug discovery and development, having formerly held Senior Leadership positions at Sitryx (Oxford), TopiVert (London), Oryzon (Barcelona) and Prosidion (Oxford). Matthew has successfully led multiple research programs in several therapeutic areas, delivering clinical candidates that have reached Phase 2 or further in oncology, immunology, metabolic disease, neurology and ophthalmology. Matthew obtained degrees from the University of Glasgow (BSc), Columbia University (MA) and the University of Birmingham (PhD) prior to postdoctoral studies at UCLA with Nobel prize winner Sir Fraser Stoddart. He is a Chartered Chemist, a Fellow of The Royal Society of Chemistry, an author of more than 40 peer-reviewed publications and an inventor on over 90 patent applications. Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK-PD, CMC and preclinical development strategies.

Job Titles:

• Member of the Board
• Partner

Michael is a Partner specialising in life sciences investments. Before joining CIC, he was a Principal in the Healthcare Practice Area at The Boston Consulting Group's (BCG) Toronto office. Michael has experience in advising multinational businesses across North America, Europe, India, and Japan. Michael was also co-founder of an early-stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael was an Investment Analyst at Oxford Capital Partners. Michael earned his DPhil in Zoology in the field of neurobiology from the University of Oxford. Michael manages CIC's investments in Bicycle Therapeutics (NASDAQ: BCYC), Congenica, Storm Therapeutics, Immutrin, PredictImmune, Sense Bio, Start Codon, and Epitopea. He is also on the board of Cambridge&, an organisation dedicated to attracting the highest quality individuals and organisations from around the globe into the Cambridge ecosystem.

Job Titles:

• Chief Scientific Officer
• Member of the Leadership Team

Oliver has overall responsibility for developing STORM's target discovery platform and for the delivery of small molecule drugs from its emerging drug discovery pipeline. Oliver worked closely with scientific founders Professors Tony Kouzarides and Eric Miska to secure the initial £12m series A investment that launched STORM, and subsequently joined the company full time in October 2016. Prior to STORM, Oliver was Programme Director at the National Institute for Health Research (NIHR), where he led the Translational Research Partnerships (TRPs) initiative and other industry-focused collaboration programmes in experimental medicine and early drug development. He served as Vice President Biology at Cellzome until the company's acquisition by GSK in 2012, and as Director of Biology at UCB Pharma until 2008. Oliver has over 15 years' drug discovery experience in inflammation, neurology and oncology. He holds a degree in Biochemistry from the Free University Berlin and a PhD in Biochemistry and Cell Biology from the Institute of Cancer Research in London.

Paul Workman is the Harrap Professor of Pharmacology and Therapeutics at The Institute of Cancer Research (ICR), London. Until August 2021, he served for seven years as Chief Executive and President of ICR, and for almost twenty years he was Director of ICR's Cancer Research UK (CRUK) Cancer Therapeutics Unit - one of the world's leading academic drug discovery organizations. In addition, Paul served as Founding Director of the CRUK Convergence Science Centre at ICR and Imperial College, and he is Co-Director of the CRUK Children's Brain Tumour Centre of Excellence at ICR and Cambridge University. Paul is an elected Fellow of the Royal Society (the UK's national academy of science), Academy of Medical Sciences, Royal Society of Chemistry, Royal Society of Biology, Royal Society of Medicine, and European Academy of Cancer Sciences, and he was awarded a CRUK Life Fellowship. Paul Workman is renowned for his research on the molecular pharmacology of targeted cancer drugs and he has been instrumental in the discovery of multiple clinical candidates and chemical probes, including those acting on protein kinases, PI3 kinases, the molecular chaperone HSP90 and the Heat Shock Factor 1 pathway. He is also the originator of the widely used Pharmacological Audit Trail for biomarker-led drug discovery and development. In addition, Paul has played a leading role in the provision of public resources for biomedical research and drug discovery, specifically the Chemical Probes Portal (of which he is Executive Director, Probe Miner and canSAR. Before joining ICR, Paul Workman spent four years in the cancer drug discovery leadership team at AstraZeneca, and prior to that worked at Glasgow and Cambridge Universities, with a sabbatical visit as a UICC Fellow to Stanford University and SRI International. Paul obtained his B.Sc. in Biological Sciences from the University of Leicester, UK, and his Ph.D. in Cancer Pharmacology from the University of Leeds, UK. Paul is a serial scientific entrepreneur. He was a scientific founder of Piramed Pharma (acquired by Roche) and Chroma Therapeutics, is a Science Partner at Nextech Invest, has collaborated extensively with biotech and pharma companies, and serves as an adviser to several biotechs. As well as serving as a Non-Executive Director at STORM Therapeutics, Paul also chairs STORM's Scientific Advisory Board. Paul Workman has received numerous honours and awards, including the Royal Society of Chemistry George and Christine Sosnovsky Award for Cancer Therapy, Royal Society of Chemistry World Entrepreneur Award, CRUK Translational Cancer Research Prize, and the International Raymond Bourgine Award for Excellence in Cancer Research. In addition, Paul led the team that won the 2012 American Association of Cancer Research Team Science Award, and under his leadership the ICR was awarded a 2017 Queens' Anniversary Prize for its world-leading research in cancer drug discovery leading to global patient impact. Paul lectures, writes and blogs about cancer research and drug discovery.

Job Titles:

• Member of the Board

Sakae has been running Taiho Ventures as founding President and CEO since its inception of 2016. Prior to joining Taiho, he was President and CEO at Astellas Venture Management and US Head of Astellas Innovation Management in 2011-2015. Prior to Astellas, he worked for Yasuda Enterprise, a Japan/US-based VC firm in 2000-2011. He has invested in several dozens of biotech companies and majority of his portfolios achieved IPOs or M&AS. During his tenure at Taiho and Astellas, he led to execute dozens of research collaboration deals with academia and biotech ventures, including several build-to-buys or spinouts.

Job Titles:

• Chairman of the Board

Tim is Chair of Storm Therapeutics Ltd, EndLyz Therapeutics Inc., and a NED of AstronauTx Ltd. He is also Chair of Schroders UK Public Private Trust plc and Senior Independent Director of Record PLC, both listed on the main market of the London Stock Exchange. Previously Tim was a Governing Board member of InnovateUK, the UK's Innovation agency, Non-Executive Director of the Cell & Gene Therapy Catapult; Chair of the UK BioIndustry Association. In the past decade, he has led two companies to exit by trade sale: as Chair of Atopix Therapeutics Limited acquired by Chiesi Farmaceutici S.P.A. in 2016; and President and Chief Executive Officer of Cellzome Inc. acquired by GlaxoSmithKline plc in 2012. Outside work, Tim plays tennis on Mondays, listens to jazz and opera, and with his wife is developing a scented garden.